Christine Zedelmayer, Senior Vice President and Chief Operating Officer of Equillium (NASDAQ:EQ), reported stock transactions on May 27-28, 2026.
She acquired 95,833 shares via employee stock options at prices ranging from $0.73 to $0.785 per share. Subsequently, she sold the same number of shares at prices between $2.70 and $2.98, generating proceeds of $267,209.
The sale was executed under a Rule 10b5-1 trading plan adopted on August 27, 2025. Equillium shares trade near their 52-week high of $3.10 after a 738% gain over the past year. According to Bond.az analysis, the stock appears overvalued relative to its fair value.
Following these transactions, Zedelmayer directly holds 62,586 shares. Several analysts (Leerink, Oppenheimer, B.Riley, Raymond James, Stifel) have recently issued positive ratings on Equillium, citing the potential of its lead asset EQ504 for inflammatory bowel disease.
